Die Anwendung der niedermolekularen Heparine in der Frauenheilkunde

L. Heilmann

doi:10.1055/s-0037-1619510

Hämostaseologie, Table of Contents

Hamostaseologie 2001; 21(03): 130-142
DOI: 10.1055/s-0037-1619510

Original article

Schattauer GmbH

Die Anwendung der niedermolekularen Heparine in der Frauenheilkunde

Low-molecular-weight heparin in gynecology

L. Heilmann

¹Abt. Gynäkologie und Geburtshilfe, Stadtkrankenhaus Rüsselsheim (Chefarzt: Prof. Dr. Lothar Heilmann)

› Author Affiliations

Abstract

Zusammenfassung

Niedermolekulare Heparine werden in der Frauenheilkunde nicht nur zur postoperativen Thromboseprophylaxe, sondern auch in der Onkologie sehr breit eingesetzt. Dabei liegt der Schwerpunkt auf dem Gebiet der Verhütung thromboembolischer Komplikationen während der Chemotherapie, aber auch direkte Wirkungen auf Tumorwachstum und Überlebenszeit der Patientinnen werden diskutiert. In der Schwangerschaft haben sich die niedermolekularen Heparine ebenfalls etabliert. Dabei steht die Verhütung von Schwangerschaftskomplikationen, wie Präeklampsie, intrauterine Wachstumsretadierung, intrauteriner Fruchttod und habitueller Abort, im Vordergrund. Thromboembolische Komplikationen haben aufgrund ihrer geringeren Inzidenz eine nachgeordnete Bedeutung.

Summary

The results of numerous clinical trials are supporting the superior efficacy and relative safety of low-molecular-weight heparin (LMWH) compared with unfractionated heparin (UFH) in gynecology/obstetrics. Several clinical trials compared LMWH with UFH for prevention of deep vein thrombosis and their results favored LMWH in reducing overall mortality in cancer patients, recurrent thromboembolic events and major bleeding complications. In addition, data indicate that LMWH given with low dose aspirin is more effective than aspirin alone in treating patients with recurrent spontaneous abortion. Because the optimal dosage of LMWH has not been established for pregnant patients, monitoring may be warranted in these cases. Women are at an estimated 5-fold increased risk for developing deep vein thrombosis during pregnancy and the puerperium compared with nonpregnant women of similar age. The LMWHs for anticoagulation are attractive because of the potential for once or twice daily dosing, decreased frequency of laboratory monitoring and dosage adjustment, safety during delivery and lower risk for heparin induced osteoporosis.

Schlüsselwörter

Schwangerschaft - postoperative Thrombose - Hormonersatztherapie (HRT) - Thrombophilie - niedermolekulare Heparine

Keywords

Pregnancy - postoperative thrombosis - hormone replacement therapy (HRT) - thrombophilia - low-molecular-weight heparin

Full Text

References

Literatur
1 Adolf J, Buttermann JG, Weidenbach A, Gmeinder F. Optimierung der postoperativen Thromboseprophylaxe in der Gynäkologie. Geburtsh Frauenheilk 1978; 38: 98-104.
2 ACOG Committee opinion. Anticoagulation with low molecular weight heparin during pregnancy. Internat J Gyn Obstet 1999; 65: 89-90.
3 ACOG. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 19, August 2000.
4 Arkel YS. Thrombosis and cancer. Seminars in Oncology 2000; 27: 362-74.
5 Arnaout MS, Kazma H, Khalil A. et al. Is there a safe anticoagulation protocol for pregnant women with prostetic valves?. Clin Exp Obstet Gynaec 1998; 25: 101-4.
6 Bachmann F, Beck E, Hohlfeld P, Holzgreve W, Huch R, Marbet G, Schneider H, von Felten A. Antikoagulation während der Schwangerschaft und im Wochenbett. Frauenarzt 1999; 40: 1412-20.
7 Backos M, Chilcott I, Ray R, Reagan L. Pregnancy complications in women with recurrent miscarriage and antiphospholipid antibodies treated with aspirin and heparin. Hum Reprod 1997; 12: 61 (abstract).
8 Backos M, Rai R, Thomas E. et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Human Reprod 1999; 14: 2876-80.
9 Ballard RM, Bradley-Watson PJ, Johnstone FD, Kenney A, McCarthey TG. Low dose of subcutaneous heparin in the prevention of deep vein thrombosis after gynecological surgery. J Obstet Gynecol Brit Cwldh 1973; 80: 469-72.
10 Baron JA, Gridley G, Weiderpass E. et al. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
11 Bergqvist D, Lindblad B. Incidence of venous thromboembolism in medical and surgical patients. In: Bergqvist D, Comerosa AJ, Nicolaides AN, Scurr JH. (eds) Prevention of venous thromboembolism. London, Los Angeles, Nicosia: Med Orion; 1994: 3-15.
12 Bick RL. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. Clin Appl Thrombosis/Hemostasis 2000; 6: 115-25.
13 Bisadze VO, Alexandrow BA, Genievskaya MG, Starchenko KV, Likova NS, Setchenov IM. Impact of LMWH (Fraxiparin) on some indices of maternal and newborne hemostases. Thromb Haemost. 1999 Suppl. 680 (abstract).
14 Bisadze VO, Alyautdin OS, Makatsaria AD. Longterm use of LMWH (Fraxiparine) in pregnancy with cardiac pathology. Thromb Haemost. 1999 Suppl. 680 (abstract).
15 Bokarewa MI, Bremme K, Blombäck M. Arg 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
16 Bona RD, Sivjee KY, Hickey AD. The efficacy and safety of oral anticoagulance in patients with cancer. Thromb Haemost 1995; 74: 1055.
17 Bonnar J, Walsh J. Prevention of thrombosis after pelvic surgery by British Dextran 70. Lancet 1972; ii: 614-6.
18 Bonnar J. Venous thromboembolism and gynecologic surgery. Clin Obstet Gynecol 1985; 28: 432-46.
19 Borstadt E, Urdahl K, Handerland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynec Scand 1988; 67: 99-103.
20 Briel RC, Doller B, Hermann CP. Thromboembolieprophylaxe bei Hysterektomien mit dem niedermolekularen Heparin Fragmin. Geburtshilf Frauenhlk 1988; 48: 160-4.
21 Büller AR. Persönliche Mitteilung. 1999
22 Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of literature. Arch Intern Med 2000; 160: 191-6.
23 Chan WS. What is the optimal management of pregnant women with valvular heart disease in pregnancy?. Haemostasis 1999; 29 (Suppl. 01) 105-6.
24 Chan WS, Ray JG. Low molecular weight heparin use during pregnancy: Issues of safety and practicality. Obstet Gynecol Survey 1999; 54: 649-54.
25 Christiansen OB. Epidemiological, immunogenetic and immunotherapeutic aspects of unexplained recurrent miscarriage. Thesis Kobenhavn 1997
26 Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-40.
27 Clarke-Pearson DL. Obstetrics and gynecology. In: Bergqvist D, Comerosa AJ, Nicolaides AN, Scurr JH. Prevention of venous thromboembolism. London, Los Angeles, Nicosia: Med Orion; 1994: 249-69.
28 Coulam CB. Immunotherapy for recurrent spontaneous abortion. Early Pregnancy: Biology and Medicine 1995; 1: 13-26.
29 Crowther MA, Spitzer K, Julian J, Ginsberg J, Johnston M, Crowther R, Laskin C. Pharmacokinetic profile of a low molecular weight heparin (Reviparin) in pregnant patients: A prospective study. Thrombos Res 2000; 98: 133-6.
30 Cummings SR, Eckert S, Krueger KA. et al. The effect of Raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999; 281: 2189-97.
31 Dalsgaard J. Treatment of venous thromboembolism with Tinzaparin during pregnancy. Ann Haematol 1999; 78: A3.
32 de Swiet M. Maternal mortality: Confidential enquiries into maternal deaths in the United Kingdom. Am J Obstet Gynaec 2000; 182: 760-6.
33 Dizon-Towson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997; 176: 883-6.
34 Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynec 2000; 107: 1116-21.
35 Farmer RDT, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ 2000; 321: 477-9.
36 Friederich P, Sanson B, Simioni P, Zanaidi S, Huisman M, Kindt I, Prandoni P, Bueller H, Girolami A, Prins M. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis. Ann Int Med 1996; 125: 955-60.
37 Gerhardt A, Scharf RE, Beckmann MW. et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.
38 Ginsberg JS. Thromboembolism and pregnancy. Thromb Haemost 1999; 82: 620-4.
39 Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Ann Rev Med 1989; 40: 79-86.
40 Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114: 524-30.
41 Girling JC, deSwiet M. Thromboembolism in pregnancy: an overview. Current opinion in Obstet Gynec 1996; 8: 458-63.
42 Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999; 130: 800-9.
43 Grady D, Wenger NK, Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 2000; 132: 689-96.
44 Grandone E, Margaglione M, Colaizzo D. Factor V Leiden, C → T MTHFR Polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052.
45 Grandone E, Margaglione M, Colaizzo D. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999; 81: 349.
46 Grandone E, Margaglione M, Colaizzo D. et al. Faktor V Leiden is associated with repeated and recurrent fetal losses. Thromb Haemost 1997; 77: 822-4.
47 Grandone E, Margaglione M, Colaizzo D. Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179: 1324-8.
48 Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6: 509-13.
49 Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-53.
50 Greer IA, de Swiet M. Thrombosis prophylaxis in obstetric and gynecology. Br J Obstet Gynecol 1993; 100: 37.
51 Greer IA. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynecology. Bailliers Clin Obstet Gynecol 1997; 11: 403-30.
52 Greer IA. The special case of venous thromboembolism in pregnancy. Haemostasis 1998; 28: 22-34.
53 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
54 Greinacher A, Warkentin TE. Treatment of heparin induced thrompocytopenia: An Overview. In: Warkentin TE, Greinacher A. (eds). Heparin induced Thrombocytopenia. New York, Basel: M. Dekker, Inc.; 2000
55 Greinacher A, Eckardt T, Mußmann J, Müller-Eckardt C. Pregnancy complicated by heparin associated thrombocytopenia: Manegement by a prospectively in vitro selected heparinoid (ORG 10172). Thromb Res 1993; 71: 123-6.
56 Gutthann SP, Rodriguez LAG, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796.
57 Hallak M, Senderowicz J, Cassel A, Shapira C, Agkai E, Auslender R, Abramovici H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
58 Harenberg J. Heparinprophylaxe in der Schwangerschaft-wann und womit?. Gynäkol Prax 2000; 24: 623-31.
59 Harenberg J, Leber G, Zimmermann R, Schmidt W. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtsh Frauenheilk 1987; 47: 15-8.
60 Heilmann L, Kruck A, Schindler E. Thromboseprophylaxe in der Gynäkologie: Doppelblindvergleich zwischen niedermolekularem (LMWH) und unfraktioniertem (UFH) Heparin. Geburtsh Frauenheilk 1989; 48: 803-7.
61 Heilmann L, von Tempelhoff GF, Herrle B, Hojnacki B, Schneider D, Michaelis HC, Wolf H. Low dose heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynäkologischen Onkologie. Geburtsh Frauenheilk 1997; 57: 1-6.
62 Heilmann L, von Tempelhoff GF, Schneider D. Prevention of thrombosis in gynecologic malignancy. Clin Appl Thrombosis/Hemostasis 1998; 4: 153-9.
63 Heilmann L, Schneider DM, von Tempelhoff GF. Antithrombotic therapy in high risk pregnancy. Hemat/Oncol Clin North America 2000; 14: 1133-50.
64 Heilmann L, Schneider DM, v. Tempelhoff GF Kuse S. Antiphospholipid antibodies and other thrombophilic defects in patients with a history of early onset severe preeclampsia or HELLP syndrome. Geburtsh Frauenheilk 1999; 59: 95-100.
65 Heinrich F. Venenthrombosen und Lungenembolien in der Schwangerschaft und im Wochenbett. Med Welt 2000; 51 (Suppl. 01) 1-32.
66 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
67 Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 13: 76-89.
68 Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149-53.
69 Herrington DM. The HERS trial results: paradigms lost?. Ann Intern Med 1999; 131: 463-6.
70 Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-8.
71 Hoibraaten E, Qvigstad E, Arnesen H. et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thromb Haemost 2000; 84: 961-7.
72 Holmes Z, Packos M, Atoyebi W, Pickering W, Regan L, Cohen H. Screening for heritable thrombophilic risk factors in a recurrent miscarriage population. Thromb Haemost 1999; (Suppl) 534.
73 Hunt BJ, Doughty HA, Majumdar G. et al. Thromboprophylaxis with low molecular-weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 78: 39-43.
74 Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190-5.
75 Kaaja R, Lehtovirta P, Venesmaa P. et al. Comparison of enoxaparin, a low-molecular weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy. Eur J Obstet Gynecol Reprod Biol 1992; 47: 141-5.
76 Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Coober DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
77 Katano K, Aoki K, Sasa H, Ogasawara M, Matsuura E, Yagami Y. Beta-2-Glykoprotein-1-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509-12.
78 Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995; 155: 366-72.
79 Kornberg A, Raziel A, Rahimini-Levene N, Yono R, Sela BA, Ron-El R. Hypercoagulability and recurrent abortion. Blood 1998; 92 (Suppl. 01) 121b.
80 Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelet syndrome. Obstet Gynecol 1998; 92: 457.
81 Krnic-Barrie S, O’Connor CR, Looney SW. et al. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med 1997; 157: 2101.
82 Kuhl M, Runnebaum B. Ist es empfehlenswert hormonale orale Kontrazeptiva vor geplanten Operationen abzusetzen. Frauenarzt 1993; 34: 730-4.
83 Kupferminc MJ, Eldor A, Steinman N. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9.
84 Laskin C, Ginsberg JS, Farine D, Crowthers M, Spitzer K, Solominka C, Ryan G, Seaward G, Ritchie K. Low molecular weight heparin and ASA-therapy in women with autoantibodies and unexplained recurrent fetal loss. Am J Obstet Gynec 1997; 176: 125 (abstract).
85 Leclerc JR, Illescas F, Jarzem P. Diagnosis of deep vein thrombosis. In: Leclerc JR. (ed) Venous thromboembolic disorders. Chicago: Lea & Febiger; 1991: 182-201.
86 Lee LH, Liaun PCY. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valves replacement. Thromb Haemost 1996; 76: 628-9.
87 Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. 1994; 309: 299-304.
88 Letsky EA, de Swiet M. Maternal haemostasis coagulation problems in pregnancy. In: Loscalzo J, Schafer AJ. Thrombosis and Hemorrhage. Oxford, London, Edinburgh: Blackwell Sci Publ; 1994: 965-98.
89 Lev-Ran O, Kramer A, Gurevitch J. et al. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000; 69: 264-6.
90 Lima F, Khamashta MA, Buranan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-6.
91 Lindhoff-Last E, Sohn C, Ehrly AM, Bauersachs RM. Aktuelles Management der Thromboembolie in Schwangerschaft und Wochenbett. Zbl Gynäk 2000; 122: 4-17.
92 Lindoff C, Ingemarson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with reduced response to activated protein C. Am J Obstet Gynecol 1997; 176: 457.
93 Linqvist P. Risk estimation and prediction of preeclampsia, IUGR, and thrombosis in pregnancy. Malmö: Thesis 1999
94 Lubbe WF, Liggins GC. Lupus anticoagulant and pregnancy. Am J Obstet Gynecol 1985; 153: 322.
95 Macklon NS, Greer IA. Venous thrombembolic disease in obstetrics and gynaecology. The Scottish experience. Scot Med J 1996; 41: 83-6.
96 McColl MD, Walker ID, Greer IA. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br Obstet Gynaec 1999; 106: 756-66.
97 McColl MD, Ramsay JE, Tait RC. et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.
98 Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608-12.
99 Mello G, Parretti E, Martini E. et al. Usefulness of screening for congenital or acquired hemostasis abnormalities in women with previous complicated pregnancies. Hemostasis 1999; 29: 197-203.
100 Meschengieser S, Salviu’ J, Lazzari M. Low molecular weight heparin (LMWH) in pregnant patients with prosthetic heart valves. Thromb Haemost 1999; Suppl 184-5.
101 Metz J, Kloss M, Molley CJO. et al. Prevalence of FVL is not increased in women with recurrent miscarriage. Clin Appl Thromb/Hemost 1997; 3: 137-40.
102 Mimuro S, Lahoud R, Beutler L, Trudinger B. Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation. Aust NZ J Obstet Gynaecol 1998; 38: 200-4.
103 Murphy RP, Donoghue C, Nallen RJ. et al. Prospective evaluation of the risk conferred by FVL and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20: 266-70.
104 Nicolaides AN, Irving D. Clinical factors and the risk of deep veinous thrombosis. In: Nicolaides AN. (ed) Thromboembolism. Lancaster: MTP; 1975: 193-204.
105 Peltier JY, de Mazancourt P, Beaufils F, Guyot B, Beumebarek Y, Doleans M, Richard L, de Rancourt E. Incidence of metabolic and hemostatic variables in 72 women with pregnancy induced hypertension. Thromb Haemost 1999; Suppl: 534.
106 Pickering W, Holmes Z, Regan L, Cohen H. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage. Br J Haematol 1998; 102: 250.
107 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-45.
108 Prandoni P, Piccioli A. Venous thromboembolism and cancer: a two-way clinical association. Frontiers in Bioscience 1997; 2: e 12-20.
109 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441-5.
110 Preston FE, Rosendaal FR, Walter ID. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913.
111 Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-7.
112 Rai R, Regan L, Hadley E, Dave M, Kohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Hematol 1996; 92: 489.
113 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-7.
114 Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10: 3301-4.
115 Rand JH, Wu XX, Guller S. Reduction of annexin V (placental anticoagulant protein I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566.
116 Rath W, Heilmann L. Gerinnungsstörungen in Gynäkologie und Geburtshilfe. Stuttgart: Thieme; 1999
117 Ray JG, Laskin CA. Folic acid and homocysteine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999; 20: 519-29.
118 Reece EA, Gabrielli S, Cullen MT. et al. Recurrent adverse pregnancy outcome and antiphospholipid antibodies. Am J Obstet Gynecol 1990; 163: 162-9.
119 Reece EA, Garofalo J, Zheng XZ, Assimakopoulos E. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment. J Reprod Med 1997; 42: 49-55.
120 Ridker PM, Miletich JP, Buring JE, Ariya AA, Priel DT, Manson JAE, Hill JA. Factor V Leiden mutation is a risk factor for recurrent pregnancy loss. Ann Int Med 1198; 128: 1000.
121 Rollin C, Blotnik H. Enoxaparin Bibliography. Rhône-Poulenc Rorer. 1999
122 Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-9.
123 Rutherford Se, Montero M, Mc Schee W. Thromboembolic disease associated with pregnancy: An 11 year review. Am J Obstet Gynecol 1991; 164: 286.
124 Rutherford SE, Phelan JP. Thromboembolic disease in pregnancy: Clinics in Perinatology. 1986; 13: 719-39.
125 Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398.
126 Sanson BJ, Lensing AWA, Prin MH. et al. Safety of low molecular weight heparin in pregnancy: A systematic review. Thromb Haemost 1999; 81: 668.
127 Sarig G, Hoffmann R, Youmis J, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with pregnancy loss associated with late pregnancy wastage. Thromb Haemost 1999; Suppl I: 226.
128 Sarret M, Toulemonde F. Meta-analysis with LMWH’s. In: Sarret M, Kher A, Toulemonde F. (eds). Low-molecular weight heparin therapy. New York, Basel: M. Dekker, Inc.; 1999
129 Schneider DM, v. Tempelhoff GF Heilmann L. Retrospective evaluation of the safety and efficacy of low molecular weight heparin as thromboprophylaxis during pregnancy. Am J Obstet Gynec 1997; 177: 1567-8.
130 Sorensen HT, Johnsen SP, Larsen H, Pedersen L, Nielsen GL, Moller M. Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynecol Scand 2000; 79: 655-9.
131 Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M. Third generation oral contraceptives and risk of venous thromboembolic disorders : an international case-control study. BMJ 1996; 321: 83-8.
132 Taberner DA, Poller L, Bursletor RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1988; 1: 272-4.
133 Tempelhoff v GF, Pollow K, Schneider D, Heilmann L. Chemotherapy and thrombosis in gynecological malignancies. Clin Appl Thrombosis/Hemostasis 1999; 5: 92-104.
134 Tempelhoff v G-F, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77: 456-61.
135 Tempelhoff v GF, Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematology/Oncology Clinics of North America 2000; 14: 1151-69.
136 Thorarensen O, Ryan S, Hunter J. et al. Factor V Leiden mutation and unrecognized cause of hemiplegic cerebral palsy, neonatal stroke and placental thrombosis. Ann Neurol 1997; 42: 372-5.
137 Triplett DA. Obstetrical complications associated with antiphospholipid antibodies. In: Coulam CB, Faulk WP, McIntyre JA. (eds) Immunological Obstetrics. New York, London: Norton Medical Books; 1992: 377-403.
138 Van Pampus MG, Dekker GA, Wolf H. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146.
139 Vincente V, Rodriguez C, Soto I, Fernandez M, Moraleda JM. Risk of thrombosis during pregnancy and postpartum in hereditary thrombophilia. Am J Haematol 1994; 46: 151.
140 Walker ID. Thrombophilia in pregnancy. J Clin Pathol 2000; 53: 573-80.
141 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynecologic surgery using labelled fibrinogen phlebography and lung scanning. J Obstet Gynaec Br Cwlth 1984; 81: 311-6.
142 Ward B, Pradhan S. Comperison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynecologic surgery. Aust NZ J Obstet Gynecol 1998; 38: 91-2.
143 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin induced thrombozytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
144 Wilson WA, Gharafi AE, Koike T, Lockshin M, Branch DW, Piete JC, Brey R, Derksen R, Harris HN, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr Rheumat 1999; 42: 1309-11.
145 Wramsby M, Bremme K, Lindner S, Blombäck M. Prevalence of factor V G1691A mutation and prothrombin 20210 A polymorphism in women with habitual abortions. Thromb Haemost 1999; Suppl: 541.
146 Younis JS, Brenner B, Okel G. et al. Activated protein C resistance and FVL mutation can be associated with first as well as second trimester recurrent pregnancy loss. Am J Reprod 2000; 43: 31-5.
147 Zacharski LR, Henderson WG, Forman WB. Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985; 16: 535.